301 results
8-K
EX-3.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
19 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:06pm
or order of business for the meeting; (ii) rules and procedures for maintaining order at the meeting and the safety of those present (including
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition. The FDA has set
8-K/A
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
trial of V116, an investigational 21-valent pneumococcal conjugate vaccine, met key immunogenicity and safety endpoints in two Phase 3 trials … to the study. In both studies, V116 had a safety profile comparable to the comparator in the studies.
Jazz Pharmaceuticals announced that the European
8-K
EX-99.1
l5bh2422 ngt
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
589z4i2u
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
EX-99.1
1l2yzn6
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
lzp12dch
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
n79xtnced9i8 bs
7 Nov 22
Ligand Reports Third Quarter 2022 Financial Results
4:04pm
425
EX-99.1
bvv4kk w74dw00xg
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
r87y84
21 Jun 22
Regulation FD Disclosure
6:19am